Monday, October 20, 2014

AnaptysBio Names New Chief Development Officer

San Diego-based therapeutic antibody developer AnaptysBio announced this morning that it has named Marco Londei as its Chief Development Officer. Dr. Londei was most recently at Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences. He also has served at Novartis, where he had been Global Head of Autoimmunity Translational Medicine. AnaptysBio is backed by Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures, Novo A/S, Numenor Ventures, WS Investments, and others.